Quarterly ResultMay 8, 2026, 02:41 PM
Nexalin Q1 Revenue Down 63.6%; Going Concern Doubt Raised
AI Summary
Nexalin Technology reported a significant decline in Q1 2026 revenue to $14,950, down 63.6% year-over-year, with net loss increasing to $2.10 million. The company disclosed substantial doubt about its ability to continue as a going concern due to ongoing operating losses and negative cash flows. Additionally, Nexalin received a Nasdaq deficiency notice for failing to meet the minimum bid price requirement. On a positive note, the FDA formally accepted the Q-Submission for its Gen-2 SYNC system for Alzheimer's and dementia.
Key Highlights
- Net revenue decreased 63.6% to $14,950 in Q1 2026 from $41,015 in Q1 2025.
- Net loss increased to $2.10 million in Q1 2026 from $1.99 million in Q1 2025.
- Accumulated deficit reached $94.96 million as of March 31, 2026.
- Net cash used in operations was $1.71 million in Q1 2026, up from $1.43 million.
- Raised $756,421 net proceeds from ATM program in Q1 2026.
- Received Nasdaq deficiency notice on Jan 21, 2026, for minimum bid price rule.
- FDA accepted Q-Submission for Gen-2 SYNC system for Alzheimer's in Oct 2025.
- Total current assets decreased to $3.29 million from $4.30 million since Dec 31, 2025.